A single-cell transcriptomics study of fetal-maternal tissue interfaces in preeclampsia identified distinct maternal and fetal cellular programs at different stages of gestation. The work points to potential therapeutic targets by separating which pathways appear to shift over time in the disease process. By analyzing cell-level gene expression rather than bulk tissue averages, the researchers mapped how maternal and fetal processes diverge across gestational stages. The results are positioned to guide downstream target validation and improve how future mechanistic studies design cohorts and endpoints.